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Highlights 
 10.6% of cases of Staphylococcus aureus bloodstream infection were due to Penicillin 
susceptible Staphylcoccus aureus (PSSA) 
 Clinicians were more likely to use benzylpenicillin for endocarditis and flucloxacillin 
for uncomplicated bloodstream infections (primary or with a skin and soft tissue 
focus) 
 Use of flucloxacillin compared with benzylpenicillin was associated with a higher 30 
day mortality 
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Abstract 
In clinical practice, differing opinion exists as to the optimal management of patients with penicillin 
susceptible Staphylococcus aureus (PSSA) bloodstream infections (BSIs).  The aim of this study was 
to compare 30-day mortality of patients treated with benzylpenicillin or flucloxacillin. We compared 30-
day mortality for patients treated with flucloxacillin or benzylpenicillin for PSSA BSIs from a large 
prospective data set from Australia and New Zealand.  We used a logistic regression model and a 
propensity score treatment analysis using inverse probability of treatment weighting.  915 patients 
were included in the study with an overall mortality rate of 12.9% (benzylpenicillin 10.5%, 33/315 and 
flucloxacillin 14.2%, 85/600).  Endocarditis was associated with benzylpenicillin treatment choice, 
whereas dialysis and skin and soft tissue infection was associated with flucloxacillin treatment.  In the 
multivariate analysis, an increased mortality was associated with flucloxacillin compared to 
benzylpenicillin (OR 1.6, 95% CI 1.0 – 2.5, p = 0.05).  When adjusted for treatment choice in the 
propensity score analysis, flucloxacillin was again associated with increased mortality (OR 1.05, 95% 
CI 1.01 – 1.1, p = 0.03).  An increase in 30-day mortality associated with flucloxacillin use suggests a 
potential benefit for benzylpenicillin therapy in patients with PSSA BSIs. 
Keywords: Penicillin susceptible S. aureus; Benzylpenicillin; Flucloxacillin; Bloodstream infection; S. 
aureus bacteraemia 
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1. Introduction 
Resistance to penicillin was discovered in Staphylococcus aureus in the mid-1940s, soon after the 
introduction of penicillin as a therapeutic agent into clinical practice.[1]  The emergence of penicillin 
resistant S. aureus (PRSA) was widely encountered in hospitals thereafter, with some reports finding 
rates of PRSA rising from 14% to 38% in less than 1 year.[2]  Two mechanisms are known that result 
in resistance to penicillin in staphylococci.  The most common, and earliest described, was by the 
production of a serine β-lactamase, known as penicillinase (PC1), which hydrolyses the β-lactam ring 
resulting in the product penicilloic acid.[2]  The second mechanism leads to resistance to beta-lactam 
agents including penicillin, by production of an altered penicillin-binding protein, PBP2a, encoded by 
mecA.[3]   Following the emergence of PRSA, a new class of anti-staphylococcal penicillins (ASPs) 
were developed that were resistant to hydrolysis of the beta-lactam ring by penicillinase. The most 
commonly used of the ASPs is flucloxacillin in Australia and nafcillin in North America. These 
isoxazolyl-penicillins, semi-synthetic penicillin derivatives, are stable during exposure to penicillinase, 
and are now the most commonly used agents for the treatment of S. aureus infections.   
 
In current clinical practice, laboratories report penicillin-susceptible S. aureus (PSSA) strains based 
upon the phenotypic absence of penicillinase, in addition to a minimum inhibitory concentration (MIC) 
below the breakpoint of 0.25 mg/L.  Yet, despite widespread use of penicillin and ASPs in clinical 
practice for more than 50 years, the optimal therapy for patients with invasive PSSA remains 
controversial.  This is particularly important as a number of recent publications have reported an 
increasing proportion of PSSA among all S. aureus clinical isolates [4-6]  In Australia, PSSA BSI rates 
are similar to those of MRSA BSI rates, with 16% and 18% of all S. aureus BSIs respectively.[7]   
 
We aimed to compare the outcome of patients with PSSA BSIs treated with benzylpenicillin or 
flucloxacillin from a large prospectively collected dataset of consecutive SAB episodes from Australia 
and New Zealand.  Our hypothesis was that patients treated with benzylpenicillin for definitive therapy 
would have lower 30-day mortality compared to those treated with flucloxacillin. 
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2. Material and Methods 
We used data from the Australia and New Zealand Co-operative Outcomes of Staphylococcal Sepsis 
(ANZCOSS) study, which collected data on all consecutive unique SAB episodes from 27 hospital-
based or independent microbiology laboratories in Australia and New Zealand, between January 2007 
to September 2013.[8]  In the ANZCOSS study, human research ethics committee or a local research 
governance office of each participating hospital or laboratory provided prospective approval.  
Individual participant consent was waived by the approving human research ethics committees.  
 
Data collected in the ANZCOSS study included patient demographics, comorbidities, treatment and 7-
day and 30-day mortality as a primary outcome measure.  As markers of infection severity were not 
included in the data collected, we included Intensive Care Unit (ICU) admission within 48 hours of the 
first positive blood culture as a surrogate for severe infection.  The central data management team 
performed data checks for completeness at regular intervals with queries sent to each participating 
laboratory.  
 
For individuals who had recurrent episodes of SAB, a separate episode was recorded if the blood 
culture was drawn more than 14 days after the previous episode. The “definitive antibiotic agent” was 
defined as the intravenous agent chosen by the treating clinician after the susceptibility profile of the 
isolate was known.  For the purpose of this analysis, we included only patients with PSSA 
bacteraemia who were treated with either benzylpenicillin or flucloxacillin. Antimicrobial susceptibility 
testing and reporting was performed by local site microbiology laboratories with most participating 
laboratories using a combination of automated testing (Vitek2, Biomerieux) and confirmatory 
phenotypic testing (nitrocefin hydrolysis method or a penicillin disc test).  
 
All statistical analysis was performed with R: A Language and Environment for Statistical Computing. 
[9]  For analysis of categorical and continuous variables we used χ2, Fisher’s exact, and Student’s t-
tests where appropriate.  Univariate logistic regression was used to compare candidate variates as 
independent variables, with 30-day mortality included in the model as the outcome variable. A 
multivariable logistic regression model was then developed based upon a backward stepwise 
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elimination of covariates which differed between the benzylpenicillin and flucloxacillin groups (Wald p 
value < 0.10).   A goodness-of-fit analysis of the model was performed after each step in the model 
using Akaike’s information criteria. 
 
In order to calculate a propensity-adjusted comparison of 30-day mortality between benzylpenicillin 
and flucloxacillin, inverse probability of treatment weighting (IPTW) was performed to address 
imbalances between treatment covariates.   To compute the Average Treatment Effect (ATE) we 
performed generalised boosted model (GBM) regression, which accounts for non-linear effects and 
interactions, for estimating propensity scores before comparing outcome using IPTW.  Only 
covariates that were clinically assessed to influence the definitive antibiotic agent choice, such as 
comorbidities, risk factors and primary focus of infection, were included in the model.  The propensity-
adjusted model was performed using the Toolkit for Weighting and Analysis of Non-equivalent Groups 
(TWANG) package and balance assessment between the benzylpenicillin and flucloxacillin groups 
was performed using the package.  In particular, standardised mean differences post balancing for all 
covariates were below 0.1 (Supplementary).[10]   
 
3. Results 
13,107 episodes of SAB were included in the ANZCOSS dataset. 11,713 episodes were excluded 
(2907 methicillin-resistant S. aureus and 8806 penicillin-resistant MSSA) based upon resistance 
phenotypes.  Of the 1,394 PSSA episodes, 307 were then excluded due to the definitive antibiotic 
treatment being antibiotics other than benzylpenicillin or flucloxacillin (cefazolin/cephalothin 108, 
vancomycin 84, not treated 62, other 161), and 64 were excluded from the final analysis due to 
missing values for 30-day vital status; leaving 915 unique PSSA episodes in the dataset.  Although in 
the ANZCOSS dataset a separate SAB episode was recorded if the blood culture was drawn greater 
than 14 days after the previous episode, no participants with PSSA BSIs were identified as having a 
separate SAB episodes within a 90 day period of a previous episode. 
 
Table 1 demonstrates demographics, risk factors, primary focus of infection and outcome variables of 
patients treated with benzylpenicillin compared to flucloxacillin.  Patients treated with benzylpenicillin 
were more likely to have a primary focus of endocarditis.  Comparatively, patients treated with 
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flucloxacillin were more likely to have a primary focus of a skin and soft tissue infection (SSTI) or a 
primary bloodstream infection.  Intensive care admission and length of stay were similar amongst the 
two groups.  Crude 7-day mortality comparison was significantly lower for benzylpenicillin (2% vs 6%, 
p <0.001), but the difference was not statistically significant for 30-day mortality (10% vs 13%, p = 
0.11). 
 
The odds ratio for 30-day mortality (Table 2) for the flucloxacillin group compared to the 
benzylpenicillin group was 1.4 (95% CI 0.9 – 2.2) in the univariate analysis, and 1.6 (95% CI 1.0 – 
2.5) in the multivariate model when adjusted for age, device-related infection, endocarditis, primary 
BSI, pneumonia and ICU admission. 
 
Factors associated with choice of benzylpenicillin versus flucloxacillin were modelled using GBM 
regression.  At baseline, the benzylpenicillin group had a higher mean of endocarditis and lower mean 
of primary BSI and SSTI (Table 1).  The maximum standardized difference and the maximum 
Kolmogorov-Smirnov statistic was 0.22 and 0.08 before IPTW, and 0.03 and 0.02 after IPTW 
(Supplementary table 1).  In the propensity score model (Table 3), patients treated with flucloxacillin 
had a higher 30-day mortality (OR 1.08, 95% CI 1.01 – 1.1) compared with those treated with 
benzylpenicillin. 
 
4. Discussion 
In this study, we compared 30-day mortality for PSSA BSIs in patients treated with benzylpenicillin 
and flucloxacillin.  In the multivariate model, an increased mortality was seen in patients treated 
flucloxacillin.  When adjusted for treatment choice in the propensity score analysis, those patients 
treated with flucloxacillin were again more likely to die than those treated by benzylpenicillin by a 
factor of about 5%.   
 
To our knowledge, this is the largest study to date in the medical literature directly comparing 
outcome of patients treated with flucloxacillin or benzylpenicillin for PSSA BSIs.  In the only other 
study to compare ASPs and benzylpenicillin, Nissen and colleagues found a non-significant reduction 
in 30-day mortality with dicloxacillin compared with benzylpenicillin (OR 0.77, 95% CI 0.38 – 1.58).[11]   
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However, in the study by Nissen et al, patients treated in the benzylpenicillin group had higher Pitt 
bacteraemia scores and greater rates of secondary manifestations such as endocarditis or 
osteomyelitis and no difference in mortality was observed in their propensity score analysis of 
benzylpenicillin and dicloxacillin.   
 
One of the potential reasons for limited comparative data may potentially be related to clinicians 
favouring ASPs over benzylpenicillin.  First, the prevalence of PSSA infections is low, reported to be 
between 5-15% of MSSA isolates based on prevalence studies.[5,6,12,13]  Therefore, as clinicians 
have become used to prescribing penicillinase resistant beta-lactams, such as flucloxacillin or 
cefazolin, for serious S. aureus infections, it is possible that benzylpenicillin is less likely to have been 
used for this indication despite laboratories reporting isolates as susceptible to penicillin.[13]  
Secondly, some clinicians and clinical groups, such as the American Heart Association, advocate 
treating both MSSA and PSSA bloodstream infections (BSIs) the same, irrespective of whether 
penicillinase is detected or not.[14]  This is typically based upon concerns over laboratories detecting 
penicillinase, with approximately 10% of S. aureus isolates that test susceptible to penicillin still 
harbouring blaZ.  However, based upon several publications, the penicillin disc method recommended 
by CLSI and EUCAST has adequate sensitivity to detect penicillinase.[15-17]   
 
Some experts however argue for the use of benzylpenicillin due to a lower MIC distribution for 
penicillin when compared with other beta-lactam agents active against S. aureus, combined with the 
ability to obtain high levels of free non-protein-bound plasma drug concentrations.[18]    Although the 
data to support this theoretical advantage are limited, many clinicians continue to use penicillin for 
therapy in this situation.  This uncertainty is significant given that 1) S. aureus bacteraemia BSI is 
associated with a high mortality and significant morbidity, 2) S. aureus is one of the most common 
organisms isolated from blood cultures, 3) S. aureus BSI is the most common reason for consultation 
with an Infectious Disease specialist (which itself has been shown to improve outcomes) and 4) a 
significant proportion of S. aureus bloodstream isolates worldwide will be reported as susceptible to 
penicillin.[19]  
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The main limitation of this study is its observational nature, with the choice of treatment likely to be 
influenced by biases.  Although a multivariate analysis and propensity score adjusted analysis were 
used to balance measured biases, it is possible that other unmeasured biases may have influenced 
the comparison.  In particular, data collection was limited to easily accessible clinical data and 
therefore, we were unable to analyse for important variables such as severity of illness, source control 
or patient comorbidities.  In addition, as we did not have specific data recorded for empiric antibiotic 
therapy, duration of therapy, whether treatment was monotherapy or combined, or dosing. It is 
possible these factors might have influenced outcome. However, these factors are unlikely to be 
unevenly distributed between those whose definitive treatment was penicillin or flucloxacillin. Only a 
randomised controlled trial would adequately be able to adjust for these potential confounders as well 
as unknown confounders. As only a small treatment difference was seen, we would suggest caution 
in interpreting superiority of benzylpenicillin over flucloxacillin, as confounding variables such as 
severity of illness, patient comorbidities and the specifics of antimicrobial therapy could not be 
included in the propensity score model.   
 
Although specific dosing for antimicrobials was not recorded on an individual patient level, 
recommended doses for flucloxacillin and benzylpenicillin did not alter significantly during the period 
of the study, with national guidelines for dosing suggesting flucloxacillin 2g Q4H and benzylpenicillin 
2.4g Q4H for critical illness or deep seated infection or flucloxacillin 2g Q6H and benzylpenicillin 1.8g 
Q4H for standard infections, with both drugs adjusted for renal impairment.[20] 
 
An interesting finding in this study was the association of 30 day mortality with episodes attributed to 
primary BSIs.  This may reflect that patients in this group were more likely to have a sepsis syndrome 
than in deep seated or SSTIs, or potentially may have died before a focus became apparent.  
Additionally, treatment duration and dosing may have differed for primary BSI than for other infections 
types and may have contributed to the higher association with mortality.  Furthermore, in the 
benzylpenicillin treated group, a higher rate of endocarditis was noted.  This suggests that clinicians in 
the Australian and New Zealand region favour benzylpenicillin for endocarditis due to PSSA, which is 
contrary to the ACA guidelines.[14]  Reasons for this are unknown, however, given the uncertainty 
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over treatment choice for PSSA BSIs, including endocarditis, further clinical studies are warranted to 
determine whether there is potential superiority for benzylpenicillin over flucloxacillin.   
 
We were also unable to test isolates for blaZ with gold standard nucleic acid amplification tests. 
However, were isolates harbouring blaZ included in the study, this would likely to have led to worse 
outcomes in the benzylpenicillin group compared to the flucloxacillin group and thus we would have 
underestimated any benefit from benzylpenicillin. 
 
Based upon this observational study, and the available evidence in the published literature, we 
believe there is sufficient evidence to support a randomised controlled trial (RCT) comparing 
benzylpenicillin and an (or multiple) ASPs.  As the main argument for benzylpenicillin treatment over 
ASPs is for potential improved outcomes due to a lower MIC distribution, favourable Pk/Pd profile and 
fewer side-effects, the study design should include assessment of efficacy for clinical outcomes as 
well as to also compare significant side effects of therapy such as hepatotoxicity and nephrotoxicity.   
 
5. Conclusion 
In this large observational cohort, we found a significant association between flucloxacillin use and all-
cause mortality in PSSA bacteraemia, after adjusting for possible confounders, when compared to 
benzylpenicillin. However, with the limitations of observational studies, this finding can only be 
assessed properly in an appropriately designed RCT.  Additional observational studies may be 
potentially helpful in estimating a sample size for a definitive study.   
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Table 1. Comparison of variables according to the treatment given 
 
 Benzylpenicillin  
N = 315 
Flucloxacillin 
N = 600 
P 
Sex (Male) 212 (67.3%) 396 (66.0%) 0.74 
Age    
Age (Median) 62 62 0.77 
Age group
a
   0.47 
Neonate (n= 23) 6 (1.9%) 17 (2.8%)  
Child (n = 39) 11 (3.5%) 28 (4.7%)  
Adult (n = 853) 298 (94.6%) 555 (92.5%)  
Risk Factors    
Dialysis 17 (5.4%) 50 (8.3%) 0.08
b
 
IDU 23 (7.3%) 35 (5.8) 0.57
c
 
Device related 88 (27.9%) 182 (30.3%) 0.39
d
 
Primary focus   <0.001
e
 
CNS Infection (n = 29) 12 (3.8%) 17 (2.8%) 0.43 
Deep Abscess 
(n = 17) 
9 (2.9%) 8 (1.3%) 0.12 
Device related infection (n = 
196) 
62 (19.7%) 134 (22.3%) 0.40 
Endocarditis (n = 81) 43 (13.7%) 38 (6.3%) <0.001 
Osteoarticular infection (n = 
176) 
69 (21.9%) 107 (17.8%) 0.16 
Primary Bloodstream Infection 
(n = 230) 
67 (21.3%) 163 (27.2%) 0.05 
Pneumonia (n= 35) 13 (4.1%) 22 (3.6%) 0.72 
Skin and soft tissue infection 
(n = 151) 
40 (12.7%) 111 (18.5%) 0.02 
Deep Seated
f
 133 (42.2%) 170 (28.4%) <0.001 
ICU admission 
ICU admission 47 (14.9%) 73 (12.2%) 0.28 
ICU admission within 48 hours 
of first positive blood culture 
31 (9.8%) 39 (6.5%) 0.09 
Outcomes    
LOS (Median) 23 23 0.59 
7d mortality 5 (2) 41 (6) <0.001 
30d mortality 33 (10) 85 (14) 0.11 
a 
Age group: Neonate <=1 years old, Child >1 - <=16 years old, Adult >16 years old;
 b
 Missing data for 
Benzylpenicillin – 26, Di/Flucloxacillin – 80; 
c 
Missing data for Benzylpenicillin – 38, Di/Flucloxacillin – 
102; 
d
 Missing data for Benzylpenicillin – 13, Di/Flucloxacillin – 35;
 e 
χ2 for 8x2 table; 
f 
Includes 
endocarditis, CNS infection, deep abscess, bone/joint infection;  
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Table 2. Logistic regression analysis of variables associated with 30-day mortality in PSSA BSI 
patients treated with benzylpenicillin and flucloxacillin 
 
Variable Unadjusted Adjusted 
 OR 95% CI P value OR 95% CI P value 
Sex       
Female (Reference) 1.0 - -    
Male 1.1 0.7 – 1.6 0.75    
Age
a
 1.03 1.02 – 
1.05 
<0.001 1.03 1.02 – 
1.04 
<0.001 
Dialysis       
No 1.0 - -    
Yes 1.02 0.4 – 2.1 0.96    
IDU       
No 1.0 - -    
Yes 0.1 0.01 – 0.6 0.04    
Primary focus       
CNS Infection 0.77 0.2 – 2.2     
Deep Abscess 0.0 NA  0.98    
Device related 0.4 0.2 – 0.7 0.004 0.7 0.4 – 1.05 0.09 
Endocarditis 1.6 0.9 – 2.9 0.12 3.1 1.5 – 6.0 0.002 
Osteoarticular infection 0.5 0.3 – 0.8 0.02    
Primary Bloodstream 
Infection 
2.6 1.8 – 3.9 <0.001 2.7 1.7 – 4.3 <0.001 
Pneumonia 2.1 0.9 – 4.5 0.20 2.8 1.1 – 6.7 0.2 
Skin and soft tissue 
infection 
0.7 0.4 – 1.2 0.23    
ICU admission within 
48 hours of first 
positive blood culture 
      
No 1.0      
Yes 2.0 1.0 – 3.5 0.03 1.9 1.1 – 3.3 0.06 
Treatment       
Benzylpenicillin 1.0      
Di/Flucloxacillin 1.4 0.9 – 2.2 0.12 1.6 1.0 – 2.5 0.05 
a
 For each year increase 
 
 
 
Table 3: Propensity score adjusted analysis of 30-day mortality 
 
Variable OR (95% CI) P value 
Treatment with 
Flucloxacillin 
1.06 (1.01 – 1.1) 0.03 
Age 1.00 (1.00 – 1.00) <0.001 
Intravenous drug use 0.9 (0.88 – 0.97) 0.002 
Endocarditis 1.1 (1.0 – 1.2) 0.04 
Primary BSI 1.1 (1.04 – 1.2) 0.002 
ICU admission within 
48 hours of first 
positive blood culture 
1.1 (0.99 – 1.2) 0.08 
 
 
 
